Sareum (LON:SAR) Posts Quarterly Earnings Results

Sareum (LON:SAR) posted its earnings results on Tuesday. The company reported GBX (0.90) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Sareum Trading Up 9.6 %

Shares of SAR traded up GBX 1.15 ($0.01) during trading hours on Thursday, hitting GBX 13.15 ($0.17). The company had a trading volume of 1,258,110 shares, compared to its average volume of 425,572. Sareum has a one year low of GBX 10 ($0.13) and a one year high of GBX 52.50 ($0.68). The company’s fifty day moving average price is GBX 17.82 and its two-hundred day moving average price is GBX 23.19. The company has a market capitalization of £16.43 million, a PE ratio of -3.11 and a beta of -1.08.

Insider Transactions at Sareum

In related news, insider Stephen Parker purchased 84,033 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of GBX 12 ($0.15) per share, with a total value of £10,083.96 ($12,983.08). Insiders own 5.02% of the company’s stock.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.